Basic science aspects of prostate cancer

Seminars in Cancer Biology

Volumn 8, Issue 1, 1997, Pages 21-27

  Dorkin, Trevor J ^b   Neal, David E ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Androgen; Androgen receptor; Growth factors; Prostate cancer; Stem cell

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; INSULIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; DEVELOPMENT; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; MALE; MORBIDITY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 0031077802     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1997.0049     Document Type: Article

References (60)

1. 1. Office For National Statistics (1996) Deaths registered by cause, and by area of residence. Population of Health Monitor DH2 96/ 2
2. 2. Merrill RM. Potosky AL, Feuer EJ (1996) Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst 88:1683-1685
3. 3. Schroder FH (1993) Prostate cancer: to screen or not to screen? BMJ 306:407-408
4. 4. Sinha AA, Hagen KA, Sibley RK, Wilson MJ, Limas C, Reddy PK, Blackard CE, Gleason DF (1986) Analysis of fixation effects on immunohistochemical localisation of prostatic specific antigen in human prostate. J Urol 136:722-727
5. 5. Reese JH, McNeal JE, Redwine EA, Samloff M, Stamey TA (1986) Differential distribution of pepsinogen II between the zones of the human prostate and the seminal vesicle. J Urol 136:1148-1153
6. 6. Cohen RJ, Glezerson G, Taylor LF, Grundle HA, Naude JH (1993) The neuroendocrine cell population of the human prostate gland. J Urol 150:365-368
7. 7. Di Sant'Agnese PA (1993) Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23:287-296
8. 8. Noordzij MA, van Weerden WM, de Ridder CM (1996) Neuroendocrine differentiation in human prostatic tumour models. Am J Pathol 149:859-871
9. 9. Verhagen APM, Aalders TW, Ramaekers FCS, Debruyne FM, Schalken JA (1988) Differential expression of keratins in the basal and luminal compartments of rat prostate epithelium during degeneration and regeneration. Prostate 13:25-38
10. 10. Isaacs JT (1987) Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model, in Benign Prostate Hyperplasia vol II (Rodgers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F, Horton R, eds) pp 85-94. NIH Publication No. 87-2881, Bethesda, MD
11. 11. English HF, Santen RJ, Isaacs JT (1987) Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229-242
12. 12. Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 28:98-106
13. 2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13:103-118
14. 14. Kyprianou N, Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562
15. 15. Kyprianou N, Bains AK, Jacobs SC (1994) Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 25:66-75
16. 16. Hochenberry DM, Nunez G, Milliman C (1990) Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
17. 17. Colombel M, Symmans E, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400
18. 18. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ (1996) Prognostic significance of bcl-2 in clinically localised prostate cancer. Am J Pathol 148:1557-1565
19. 19. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445
20. 20. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hseih J, Tu S, Campbell ML (1992) Expression of the proto-oncogene bcl-2 in prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
21. 21. Zhang X, Colombel M, Raffo A, Buttyan R (1994) Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. Biochem Biophys Res Commun 198:1189-1194
22. 22. Navone N, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenback AC, Conti CJ (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1699
23. 23. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC (1996) bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74:1258-1262
24. 24. Beato M (1989) Gene regulation by steroid hormones. Cell 56:335-344
25. 25. Riegman PHJ, Vliestra RJ, van der Korput JAGM, Brinkmann AO, Trapman J (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921-1930
26. 26. Murtha P, Tindall DJ, Young CY (1993) Androgen induction of a human prostate-specific kallikrein, hKLK2: Characterisation of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32:6459-6464
27. 27. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ (1990) Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50:5382-5386
28. 28. Chodak GW, Krane DM, Puy LA, Takeda H, Johnson K, Chang C (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147:798-803
29. 29. van der Kwast TH, Schalken J, Ruizeveld de Winter JA (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193
30. 30. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper JGM, Jenster G, Trapman J, Brinkmann AO, Mulder E (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens [Review]. J Steroid Biochim Mol Biol 41:665-669
31. 31. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864
32. 32. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414
33. 33. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89:6319-6323
34. 34. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550
35. 35. Ruizeveld de Winter JA, Janssen PJA, Sleddens HMEB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, Santesse AB, Schroder FH, van der Kwast TH (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746
36. 36. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Eng J Med 332:1393-1398
37. 37. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu E, Keating A (1993) Androgen induced inhibition of cell proliferation in an androgen insensitive prostate cancer cell line (PC3) transfected with a human androgen receptor complementary DNA (cDNA). Cancer Res 53:1304-1311
38. 38. Payson RA, Canatan H, Chotani MA, Wang W, Harris SE, Myers RL, Chiu I (1993) Cloning of two novel forms of human acidic fibroblast growth factor (aFGF) mRNA. Nucleic Acids Res 21:489-495
39. 39. Nakomoto T, Chang C, Li A, Chodak GW (1992) Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52:571-577
40. 40. Leung HY, Dickson C, Robson CN, Neal DE (1996) Overexpression of fibroblast growth factor-8 in human prostate cancer. Oncogene 12:1833-1835
41. 41. MacArthur CA, Lawshe A, Shankar DB, Heikinheimo M, Shackleford GM (1995) FGF-8 isoforms differ in NIH3T3 cell transforming potential. Cell Growth Diff 6:817-825
42. 42. Schmitt JF, Hearn MT, Risbridger GP (1996) Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. J Steroid Biochem Mol Biol 57:173-178
43. 43. Yan G, Fukabori Y, McBride G, Nikolarapolous S, McKeehan WL (1993) Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13:4513-4522
44. 44. MacArthur CA, Lawshe A, Xu A, Santos-Ocampo S, Heikinheimo M, Chellaiah AT, Ornitz DN (1995) FGF-8 isoforms activate receptor splice variants that are expressed in mesenchymal regions of mouse development. Development 121:3603-3613
45. 45. Ittman M, Mansukhani A (1997) Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 157:351-356
46. 46. Morris GL, Dodd JG (1990) Epidermal growth factor receptor mRNA levels in human prostatic tumours and cell lines. J Urol 143:1272-1274
47. 47. MacDonald A, Habib FK (1992) Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 65:177-182
48. 48. MacDonald A, Chisholm GD, Habib FK (1990) Production and response of a human prostatic cancer cell line to transforming growth factor-like molecules. Br J Cancer 62:579-584
49. 49. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K (1993) An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumours. Prostate 23:9-23
50. 50. Glynne-Jones E, Goddard L, Harper ME (1996) Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissues. Hum Pathol 27:688-694
51. 51. Cheng KZ, Ramsay E, Pettigrew N, Cunha RD, Jason M, Dodd JG (1993) Expression of mRNA for epidermal growth factor, transforming growth factor-α and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126:151-158
52. 52. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J (1994) Mechanism of action of the TGF-β receptor. Nature 370:341-347
53. 53. Steiner MS, Barrack ER (1992) Transforming growth factor-β1 overproduction in prostate cancer; effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25
54. 54. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC (1995) Transforming growth factor-β: a comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628-635
55. 55. Kim IY, Ahn H, Zeiner DJ, Shaw JW, Sensibar JA, Kim J, Kato M, Lee C (1996) Genetic change in transforming growth factor-β (TGF-β) receptor type I correlates with in sensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 56:44-48
56. 56. Sehgal I, Baley PA, Thompson TC (1996) Transforming growth factor-β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56:3359-3365
57. 57. Iwamura M, Sluss PM, Casamento JB, Cockett ATK (1991) Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrin Metab 73:401-407
58. 58. Pietrzowski Z, Mulholland G, Gomella L, Hameson BA, Weinike D, Baserga R (1993) Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106
59. 59. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumour cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
60. 60. Morton DM, Barrack ER (1995) Modulation of transforming growth factor-β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55:3596-2602